Invivyd Logo
HARNESSING A NOVEL APPROACH

Scientific publications

<
Preliminary safety results from a phase 1 first in human study of VYD222: an extended half-life monoclonal antibody (mAb) in development for COVID-19 prevention.Mahoney et al. IDWeek. 2023.
Prevention of COVID-19 following a single intramuscular administration of adintrevimab: results from a phase 2/3 randomized, double-blind, placebo-controlled trial (EVADE).Ison et al. Open Forum Infectious Diseases. 2023.
Efficacy and safety of adintrevimab (ADG20) for the treatment of high-risk ambulatory patients with mild or moderate COVID-19: results from a phase 2/3, randomized, placebo-controlled trial (STAMP) conducted during Delta predominance and early emergence of Omicron.Ison et al. Open Forum Infectious Diseases. 2023.
Assessment of effect of adintrevimab on COVID-19 vaccine response.Tosh et al. ISIRV-AVG. 2023.
NVD200 potently neutralizes Omicron and its sublineages.West et al. ECCMID. 2023.
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers.Schmidt et al. Science Translational Medicine. 2023.
ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants.Kaku et al. ECCMID. 2022.
Population pharmacokinetics of ADG20, an extended–half-life monoclonal antibody being developed for the treatment and prevention of COVID-19.Rubino et al. ECCMID. 2022.
Results from the phase 2/3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of adintrevimab (ADG20) in the treatment of ambulatory participants with mild or moderate COVID-19 (STAMP).Popejoy et al. ASM Microbe. 2022.
Broad and potent in vitro neutralization of SARS-CoV-2 variants by ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19.Kaku et al. ISIRV-WHO. 2021.
Evaluating the safety, tolerability, and pharmacokinetics of ADG20, a half-life–extended monoclonal antibody (mAb) in development for the prevention and treatment of COVID-19: a preliminary analysis of a randomized phase 1 study.Schmidt et al. ISIRV-WHO. 2021.
A whole-body quantitative system pharmacology physiologically based pharmacokinetic model that a priori predicts pharmacokinetics of ADG20: an extended half-life monoclonal antibody being developed for the treatment and prevention of COVID-19.Van Wart et al. ID Week. 2021.
A whole-body quantitative system pharmacology physiologically based pharmacokinetic model to support dose selection of ADG20: an extended half-life monoclonal antibody being developed for the treatment of coronavirus disease (COVID-19).Tarbell et al. ID Week. 2021.
Use of a whole-body quantitative system pharmacology physiologically based pharmacokinetic model to support ADG20 dose selection for the prevention of coronavirus disease (COVID-19).Van Wart et al. ID Week. 2021.